Rebecca Sutton
About Rebecca Sutton
Rebecca Sutton serves as the Director of Clinical Operations at Erasca, Inc., where she has worked since 2021. With a strong background in clinical research, she has held leadership roles at Nektar Therapeutics and Genentech, focusing on innovative cancer treatments.
Work at Erasca
Rebecca Sutton serves as the Director of Clinical Operations at Erasca, Inc., a position she has held since 2021. In this role, she is responsible for overseeing clinical research projects that focus on innovative discovery research aimed at targeting oncogene drivers of tumor malignancies. Her leadership is pivotal in guiding the clinical team and ensuring the successful execution of clinical studies.
Previous Experience at Nektar Therapeutics
Before joining Erasca, Rebecca Sutton worked at Nektar Therapeutics as the Associate Director of Clinical Operations from 2019 to 2021. During her tenure, she contributed to the management of clinical operations, enhancing the efficiency and effectiveness of clinical research initiatives within the organization.
Career at Genentech
Rebecca Sutton's career includes a significant role at Genentech, where she served as a Global Senior Clinical Trial Leader from 2005 to 2019. Over her 14 years at Genentech, she gained extensive experience in planning, implementing, and managing clinical studies from concept to completion, solidifying her expertise in clinical operations.
Leadership and Mentoring
In her current role at Erasca, Rebecca Sutton provides leadership and mentoring to other members of the Clinical team. Her guidance helps to foster a collaborative environment and supports the professional development of her colleagues, contributing to the overall success of clinical operations.
Clinical Research Expertise
Rebecca Sutton possesses extensive experience in clinical research, particularly in the area of oncology. Her work focuses on managing clinical studies that aim to address oncogene drivers of tumor malignancies, showcasing her commitment to advancing cancer research and treatment.